Aslan Pharmaceuticals Ltd (ASLN)

$0.6

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $0.60
    $0.69
    $0.60
    downward going graph

    0.0%

    Downside

    Day's Volatility :13.49%

    Upside

    13.49%

    downward going graph
  • $0.48
    $22.96
    $0.60
    downward going graph

    20.83%

    Downside

    52 Weeks Volatility :97.93%

    Upside

    97.39%

    downward going graph

Returns

PeriodAslan Pharmaceuticals LtdIndex (Russel 2000)
3 Months
-83.52%
0.0%
6 Months
-86.25%
0.0%
1 Year
-97.33%
0.0%
3 Years
-99.47%
-19.4%

Highlights

Market Capitalization
1.7M
Book Value
- $7.7
Earnings Per Share (EPS)
-16.0
Wall Street Target Price
72.0
Profit Margin
-291.89%
Operating Margin TTM
-291.03%
Return On Assets TTM
-53.69%
Return On Equity TTM
-426.64%
Revenue TTM
12.0M
Revenue Per Share TTM
5.51
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
79.8M
EBITDA
-34.9M
Diluted Eps TTM
-16.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-26.72
EPS Estimate Next Year
-18.8
EPS Estimate Current Quarter
-0.61
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Aslan Pharmaceuticals Ltd(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 11900.0%

Current $0.60
Target $72.00

Technicals Summary

Sell

Neutral

Buy

Aslan Pharmaceuticals Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aslan Pharmaceuticals Ltd
Aslan Pharmaceuticals Ltd
-76.56%
-86.25%
-97.33%
-99.47%
-99.53%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aslan Pharmaceuticals Ltd
Aslan Pharmaceuticals Ltd
NA
NA
NA
-26.72
-4.27
-0.54
NA
-7.7
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aslan Pharmaceuticals Ltd
Aslan Pharmaceuticals Ltd
Buy
$1.7M
-99.53%
NA
-291.89%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Aslan Pharmaceuticals Ltd

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 157.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 300.1%

Institutional Holdings

  • Bvf Inc

    4.64%
  • Velan Capital Investment Management LP

    2.76%
  • Shay Capital LLC

    1.77%
  • Sio Capital Management, LLC

    1.12%
  • Schonfeld Strategic Advisors LLC

    0.65%
  • Renaissance Technologies Corp

    0.54%

Company Information

aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.

Organization
Aslan Pharmaceuticals Ltd
Employees
35
CEO
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
Industry
Health Technology

FAQs